Regulation of arginine vasopressin in enuretic children under fluid restriction.

BACKGROUND Treatment of primary nocturnal enuresis using 1-deamino-8-D-arginine-vasopressin is based on the hypothesis that antidiuretic hormone (arginine vasopressin [AVP]) secretion is insufficient during the night. Persisting doubts about the theoretical background of this treatment and first results pointing to a different AVP regulation in children with nocturnal enuresis were the motives for the present study. OBJECTIVE To determine if children with primary nocturnal enuresis have different AVP levels during fluid restriction when compared with normal controls. METHODS Twenty-three children with nocturnal enuresis (median age, 11 years) were compared with a corresponding control group of 18 healthy children. Plasma osmolality, urine osmolality, and plasma AVP concentrations were determined before and after a defined fluid restriction. RESULTS Regarding plasma and urine osmolality, no differences were found between the two groups. AVP levels after fluid restriction, however, showed significant differences. To maintain osmolality, the plasma AVP concentrations of the controls rose to a median value of 5.7 pg/mL (range: 0.9-29.0 pg/mL) in comparison to a median of 14.0 pg/mL (range: 3.5-64.0 pg/mL, P =. 015) for the enuretic children. CONCLUSION The results are consistent with the established fact that AVP secretion is a function of plasma osmolality. They contradict the hypothesis that enuretic children have a AVP deficiency that has to be supplemented. Rather, the results point to a defect at the AVP receptor level or of the signal transduction pathway.

[1]  A. Monga,et al.  Voiding dysfunction , 2001, Current opinion in obstetrics & gynecology.

[2]  R. Liebert,et al.  Disorders of Elimination , 2000 .

[3]  P. Eggert,et al.  Antidiuretic hormone regulation in patients with primary nocturnal enuresis. , 1995, Archives of disease in childhood.

[4]  R. Donald,et al.  Short-term secretion patterns of corticotropin-releasing hormone, arginine vasopressin and ACTH as shown by intensive sampling of pituitary venous blood from horses. , 1994, Neuroendocrinology.

[5]  R. Fefferman DDAVP approval question. , 1994, Pediatrics.

[6]  B. V. van Oost,et al.  Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. , 1994, Science.

[7]  H. Watanabe,et al.  Treatment system for nocturnal enuresis according to an original classification system. , 1994, European urology.

[8]  L. Rappaport The treatment of nocturnal enuresis--where are we now? , 1993, Pediatrics.

[9]  E. Isenberg,et al.  Vasopressin deficiency in primary nocturnal enuresis. Results of a controlled prospective study. , 1993, European urology.

[10]  E. B. Pedersen,et al.  Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. , 1989, The American journal of physiology.

[11]  S. Ball,et al.  Diurnal change in plasma atrial natriuretic peptide concentrations. , 1987, Clinical science.

[12]  K. Schärer,et al.  Determinants of Plasma Arginine‐Vasopressin in Children , 1986, Acta paediatrica Scandinavica.

[13]  G. Kovacs,et al.  A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. , 1983, Science.

[14]  F. Goodwin,et al.  Effects of vasopressin on human memory functions. , 1981, Science.

[15]  G. Robertson,et al.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. , 1973, The Journal of clinical investigation.

[16]  B. Starfield Functional bladder capacity in enuretic and nonenuretic children. , 1967, The Journal of pediatrics.

[17]  T. Hägglund Enuretic children treated with fluid restriction or forced drinking. A clinical and cystometric study. , 1965, Annales paediatriae Fenniae.

[18]  D. Vulliamy The Day and Night Output of Urine in Enuresis , 1956, Archives of disease in childhood.

[19]  E. Hinden,et al.  The Classification of Enuresis , 1953, Archives of disease in childhood.